宫内节育器：如何在分子世界部署这一战略？

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-09-10 DOI:10.1158/1078-0432.ccr-24-2034

Paul Johannet,Claire F Friedman

引用次数: 0

摘要

对于希望保留生育能力的非典型子宫内膜增生或 1 级子宫内膜癌患者，可以安全地采用孕激素治疗。最近的一项研究表明，左炔诺孕酮宫内节育器可带来持久的临床益处，并确定了复发和耐药的可能免疫机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The intrauterine device: how to deploy this strategy in the molecular world?

Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or Grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.